Chlorpromazine 100mg Tablets
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Chlorpromazine 100mg Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 100 mg of Chlorpromazine Hydrochloride B.P.
Excipients with known effect:
Lactose
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Round, white, film-coated tablets intended for oral administration to human beings.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Chlorpromazine is a phenothiazine neuroleptic. It is indicated in the following conditions:
Schizophrenia and other psychoses (especially paranoid) mania and hypomania.
Anxiety, psychomotor agitation, excitement, violent or dangerously impulsive behaviour. Chlorpromazine is used as an adjunct in the short-term treatment of these conditions.
Intractable hiccup.
Nausea or vomiting associated with terminal illness (where other drugs have failed or are not available.)
Childhood schizophrenia and autism.
4.2 Posology and method of administration
Posology
Dosage varies both with the individual and with the purpose for which the drug is being used. The dosage should be low to begin with and increased, gradually, under close supervision until the optimum level of control is achieved.
Schizophrenia, other psychoses, anxiety and agitation childhood schizophrenias and autism
Adults
Initially 25mg three times daily or 75mg at bedtime, increasing by daily amounts of 25mg to the effective maintenance dose. The usual maintenance dose is in the range of 75 to 300mg daily, although some patients may require up to 1.0g daily.
Paediatric population
Children under 1 year: Do not use unless need is life saving.
Children 1-5 years: 0.5mg/kg bodyweight every 6-8 hours. Dosage is not advised to exceed 40 mg daily.
Children 6-12 years: 0.5mg/kg bodyweight every 6-8 hours. Dosage of 75 mg daily.
Older people or debilitated patients
Doses in the lower range for adults should be sufficient to control symptoms i.e. 25 mg 8 hourly.
Hiccup
Adults
25-50mg three to four times daily.
Paediatric population
The safety and efficacy of Chlorpromazine in children aged 0 to 12 years have not yet been established.
No data available.
Nausea and vomiting of terminal illness
Adults
10-25mg every 4 to 6 hours.
Paediatric population Children under 1 year Do not use unless need is life saving.
Children 1-5 years
0.5mg/kg 6-8 hourly. It is advised that maximum daily dosage should not exceed 40 mg.
Children 6-12 years
0.5mg/kg every 6-8 hours. It is advised that maximum daily dosage should not exceed 75 mg.
Older people or debilitated patients Not recommended.
Method of administration
Oral.
Swallow the tablets with a glass of water.
4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
• Bone marrow depression
• Risk of angle-closure glaucoma
• Risk of urinary retention related to urethroprostatic disorders
• History of agranulocytosis
• Nursing mothers (see section 4.6)
• Citalopram, escitalopram
4.4 Special warnings and precautions for use
All patients must be advised that, if they experience fever, sore throat or any other infection, they should inform their physician immediately and undergo a complete blood count. Treatment will be discontinued if any marked changes (hyperleucocytosis, granulocytopenia) are observed in the latter.
As agranulocytosis has been reported, regular monitoring of the complete blood count is recommended. The occurrence of unexplained infections or fever may be evidence of blood dyscrasia (see section 4.8) and requires immediate haematological investigation.
Neuroleptic malignant syndrome
Treatment must be interrupted in the event of unexplained hyperpyrexia since this can be one of the signs of neuroleptic malignant syndrome (pallor, hyperthermia, autonomic dysfunction, altered consciousness, muscle rigidity). Signs of autonomic instability such as hyperhydrosis and irregular blood pressure, can precede the onset of hyperthermia and as such constitute premonitory signs of this syndrome. While this neuroleptic-related effect can
be of idiosyncratic origin, certain risk factors such as dehydration brain damage would seem to indicate a predisposition.
Chlorpromazine should be avoided in patients with hypothyroidism, phaeochromocytoma, myasthenia gravis and prostate hypertrophy. It should be avoided in patients known to be hypersensitive to phenothiazines or with history of narrow angle glaucoma or agranulocytosis.
Acute withdrawal symptoms, including nausea, vomiting and insomnia, have very rarely been reported following the abrupt cessation of high doses of neuroleptics. Relapse may also occur, and the emergence of extrapyramidal reactions has been reported. Therefore, gradual withdrawal is advisable.
In schizophrenia, the response to neuroleptic treatment may be delayed. If treatment is withdrawn, the recurrence of symptoms may not become apparent for some time.
QT prolongation
Neuroleptic phenothiazines may potentiate QT interval prolongation which increases the risk of onset of serious ventricular arrhythmias of the torsade de pointes type, which is potentially fatal (sudden death). QT prolongation is exacerbated, in particular, in the presence of bradycardia, hypokalaemia and congenital or acquired (i.e. drug induced) QT prolongation.
If the clinical situation permits, medical and laboratory evaluations should be performed to rule out possible risk factors before initiating treatment with a neuroleptic agent and as deemed necessary during treatment (see section 4.8).
Where clinically possible, the absence of any factors favouring the onset of ventricular arrhythmias should be ensured before administration:
• Bradycardia less than 55 beats per minute;
• Hypokalemia;
• Hypocalcaemia;
• Hypomagnesaemia;
• Starvation;
• Alcohol abuse;
• Concomitant therapy with other drugs known to prolong the QT interval;
• Congenital long QT interval;
• Ongoing treatment with any drug which could induce marked bradycardia (<55 beats per minute), hypokalemia, intracardiac conduction depression or QT prolongation (see section 4.5).
• In patients with a history of cardiovascular disorders, e.g. QT prolongation, significant bradycardia (<50 beats per minute), a recent acute myocardial infarction, uncompensated heart failure, or cardiac arrhythmia.
With the exception of emergencies, it is recommended that the initial work up of patients receiving a neuroleptic should include an ECG.
Except under exceptional circumstances, this drug must not be administered to patients with Parkinson's disease.
The concomitant use of chlorpromazine with lithium, other QT prolonging agents, and dopaminergic antiparkinsonium agents is not recommended (see Section 4.5).
The onset of paralytic ileus, potentially indicated by abdominal bloating and pain, must be treated as an emergency (see section 4.8).
Venous thromboembolism
Cases of venous thromboembolism (VTE), sometimes fatal have been reported with antipsychotic drugs. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with Chlorpromazine and preventive measures undertaken.
Stroke
In randomised clinical trials versus placebo performed in a population of elderly patients with dementia and treated with certain atypical antipsychotic drugs, a 3-fold increase of the risk of cerebrovascular events has been observed. The mechanism of such risk increase is not known. An increase in the risk with other antipsychotic drugs or other populations of patients cannot be excluded. Chlorpromazine should be used with caution in patients with stroke risk factors.
Older people with Dementia
Elderly patients with dementia-related psychosis treated with antipsychotics drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death in clinical trials with atypical antipsychotics were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear.
As with all antipsychotic drugs, chlorpromazine should not be used alone where depression is predominant. However, it may be combined with antidepressant therapy to treat those conditions in which depression and psychosis coexist.
Chlorpromazine is not licensed for the treatment of dementia-related behavioural disturbances.
Because of the risk of photosensitisation (see section 4.8), patients should be advised to avoid exposure to direct sunlight.
In those frequently handling preparations of phenothiazines, the greatest care must be taken to avoid contact of the drug with the skin.
Hyperglycaemia or intolerance to glucose has been reported in patients treated with chlorpromazine. Patients with established diagnosis of diabetes mellitus or with risk factors for the development of diabetes who are started on Chlorpromazine, should get appropriate glycaemic monitoring during treatment (see section 4.8).
The following populations must be closely monitored after administration of chlorpromazine:
- Epileptics, since chlorpromazine may lower the seizure threshold. Treatment must be discontinued if seizures occur.
- Elderly patients presenting with heightened susceptibility to orthostatic hypotension, sedation and extrapyramidal effects; chronic constipation (risk of paralytic ileus), and potentially prostatic hypertrophy. It should be used with caution particularly during very hot or cold weather (risk of hyper - hypothermia)
- Patients presenting with certain forms of cardiovascular disease, since this class of drug has quinidine-like effects can induce tachycardia and hypotension.
- Patients with severe liver and/or renal failure because of the risk of accumulation. Patients on long-term treatment should receive regular ophthalmological and haematological examinations.
- Patients are strongly advised not to consume alcohol and alcohol-containing drugs throughout treatment (see section 4.5)
- Owing to the risk of hypotension, patients should be advised to remain supine for at least half an hour after injection. Tachycardia as well as local pain or nodule formation may occur after intramuscular administration. Blood pressure should be monitored when receiving parenteral chlorpromazine
- Since there is a potential impact on cognitive function, children should undergo a yearly clinical examination to evaluate learning capacity. The dosage should be adjusted regularly as a function of the clinical status of the child.
Chlorpromazine 100 mg tablets contain Lactose:
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
4.5 Interaction with other medicinal products and other forms of interaction
Adrenaline must not be used in patients overdosed with chlorpromazine.
Anticholinergic drugs may reduce the antipsychotic effect of chlorpromazine and the mild anticholinergic effect of chlorpromazine can be enhanced by other anticholinergic drugs possibly leading to constipation, heat stroke, etc.
The action of some drugs may be opposed by chlorpromazine; these include amphetamine, levodopa, clonidine, guanethidine and adrenaline.
Increases or decreases in the plasma concentrations of a number of drugs, e.g. propranolol, phenobarbital have been observed but were not of clinical significance.
Simultaneous administration of desferoxamine and prochlorperazine has been observed to induce a transient metabolic encephalopathy characterised by loss of consciousness for 48 to 72 hours. It is possible this may occur with chlorpromazine since it shares many of the pharmacological properties of prochlorperazine.
There is an increased risk of agranulocytosis when neuroleptics are used concurrently with drugs with myelosuppressive potential, such as carbamazepine or certain antibiotics and cytotoxics.
Combinations contraindicated
Citalopram and escitalopram are contraindicated.
Combinations not recommended
Dopaminergic antiparkinsonium agents (amantadine, bromocriptine, cabergoline, levodopa, lisuride, pergolide, piribedil and ropirinole) are not recommended: reciprocal antagonism of the antiparkinsonism agent and neuroleptic (see section 4.4). Neuroleptic-induced extrapyramidal syndrome should be treated with an anticholinergic rather than a dopaminergic antiparkinsonism agent (dopaminergic receptors blocked by neuroleptics).
Levodopa: reciprocal antagonism of levodopa and the neuroleptic. In Parkinson's patients, it is recommended to use the minimal doses of each drug.
QT prolonging drugs: There is an increased risk of arrhythmias when neuroleptics are used with concomitant QT prolonging drugs (including certain antiarrhythmics, antidepressants and other antipsychotics including sultopride) and drugs causing electrolyte imbalance (see section 4.4). Diuretics, in particular causing hypokalaemia, should be avoided but, if necessary, potassium-sparing diuretics are preferred.
Alcohol: alcohol potentiates the sedative effect of neuroleptics. Changes in alertness can make it dangerous to drive or operate machinery. Alcoholic
beverages and medication containing alcohol should be avoided (see section 4.4).
Lithium (high doses of neuroleptics): concomitant use can cause confusional syndrome, hypertonia and hyper-reflexivity, occasionally with a rapid increase in serum concentrations of lithium (see section 4.4). There have been rare cases of neurotoxicity. Lithium can interfere with the absorption of neuroleptic agents.
Combinations requiring precautions
Anti-diabetic agents: concomitant administration of high chlorpromazine doses (100mg/day) and anti-diabetic agents can lead to an increase in blood sugar levels (decreased insulin release). Forewarn the patient and advise increased self-monitoring of blood and urine levels. If necessary, adjust the anti-diabetic dosage during and after discontinuing neuroleptic treatment.
Topical gastrointestinal agents (magnesium, aluminium and calcium salts, oxides and hydroxides): decreased GI absorption of phenothiazine neuroleptics. Do not administer phenothiazine neuroleptics simultaneously with topical GI agents (administer more than 2 hours apart if possible).
Combinations to be taken into consideration
Antihypertensive agents: potentiation of the antihypertensive effect and risk of orthostatic hypotension (additive effects). Severe postural hypotension occurs when chlorpromazine is administered concomitantly with ACE inhibitors. Guanethidine has adverse clinically significant interactions documented.
Atropine and other atropine derivatives: imipramine, antidepressants, histamine H1-receptor antagonists, anticholinergic antiparkinsonism agents, atropinic antispasmodics, dispyramide: build-up of atropine-associated adverse effects such as urinary retention, constipation and dry mouth, heat stroke etc.
Other CNS depressants: morphine derivatives (analgesics, antitussives and substitution treatments), barbiturates, benzodiazepines, anxiolytics other than benzodiazepines, hypnotics sedative antidepressants, histamine H1 receptor antagonists, central antihypertensive agents increased central depression Changes in alertness can make it dangerous to drive or operate machinery.
4.6 Fertility, pregnancy and lactation
Pregnancy
There is inadequate evidence of the safety of chlorpromazine in human pregnancy. There is evidence of harmful effects in animals. Like other drugs, it should be avoided in pregnancy unless is the physician considers it essential. It may occasionally prolong labour and at such time should be withheld until the cervix is dilated 3-4cm.
Possible adverse effects on the foetus include lethargy or paradoxical hyperexcitability, tremor and low Apgar score.
A large amount of exposure to chlorpromazine during pregnancy did not reveal any teratogenic effect.
It is advised to keep an adequate maternal psychic balance during pregnancy in order to avoid decompensation. If a treatment is necessary to ensure this balance, the treatment should be started or continued at effective dose all through pregnancy.
Neonates exposed to antipsychotics (including Chlorpromazine) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, bradycardia, tachycardia, feeding disorder, meconium ileus, delayed meconium passage, abdominal bloating. Consequently, newborns should be monitored carefully in order to plan appropriate treatment.
Breast-feeding
Chlorpromazine may be excreted in milk, therefore breastfeeding should be suspended during treatment.
Fertility
A decrease in fertility was observed in female animals treated with chlorpromazine. In male animals data are insufficient to assess fertility.
In humans, because of the interaction with dopamine receptors, chlorpromazine may cause hyperprolactinaemia which can be associated with impaired fertility in women (see section 4.8). In men, data on consequences of hyperprolactinaemia are insufficient with regard to fertility.
4.7 Effects on ability to drive and use machines
Chlorpromazine has major influence on the ability to drive and use machines. Patients should be warned about drowsiness during the early days of treatment.
4.8 Undesirable effects
|
System Organ Class |
Very common (>1/10) |
Common (>1/100 to <1/10) |
Not known (cannot be estimated from available data) |
|
Blood and lymphatic system disorders |
Agranulocytosis Leukopenia | ||
|
Immune system disorders |
Systemic lupus erythematosus Bronchospasm Anaphylactic reaction |
|
Endocrine disorders |
Hyperprolactinae mia Amenorrhoea |
Galactorrhoea Gynaecomastia Impotence | |
|
Metabolism and nutrition disorders |
Glucose tolerance impaired (see section 4.4) |
Hyperglycaemia (see section 4.4) Hypertriglyceridae mia Hyponatraemia Inappropriate antidiuretic hormone secretion | |
|
Psychiatric disorders |
Anxiety |
Lethargy Mood altered Erectile dysfunction Female sexual arousal disorder | |
|
Nervous system disorders |
Sedation2 Somnolence2 Dyskinesia (Acute dystonias or dyskenias, usually transitory are more common in children and young adults and usually occur within the first 4 days of treatment or after dosage increases.) Tardive dyskinesia3 Extrapyramidal disorder Akathisia-often after large initial dose |
Hypertonia Convulsion |
Torticollis Oculogyric crisis Trismus Akinesia Hyperkinesia Neuroleptic malignant syndrome (hyperthermia, rigidity, autonomic dysfunction and altered consciousness) (see section 4.4) Parkinsonism (more common in adults and the elderly. It usually develops after weeks or months of treatment) to include tremor, rigidity or other features of Parkinsonism |
|
Eye disorders |
Accommodation disorder4 Deposit eye5 Ocular changes7 | ||
|
Cardiac disorders |
ECG changes include Electrocadiogram QT prolonged (as with other neuroleptics) (see |
Cardiac arrhythmias, including Ventricular arrhythmia and atrial arrhythmia, |
|
section 4.4), ST depression, U-Wave and T-Wave changes. |
Atrioventricular block, Ventricular fibrillation Ventricular tachycardia Torsade de pointes Cardiac arrest has been reported during neuroleptic phenothiazine therapy, possibly related to dosage. Pre-existing cardiac disease, old age, hypokalaemia and concurrent tricyclic antidepressants may predispose. Sudden death/ Sudden cardiac death (with possible causes of cardiac origin as well as cases of unexplained sudden death, in patients receiving neuroleptic phenothiazines) (see section 4.4) | ||
|
Vascular disorders |
Orthostatic hypotension (Elderly or volume depleted subjects are particularly susceptible: it is more likely to occur after intramuscular administration) |
Embolism venous Pulmonary embolism (sometimes fatal) Deep vein thrombosis (see section 4.4) | |
|
Respiratory, thoracic and mediastinal disorders |
Respiratory depression Nasal congestion | ||
|
Gastrointestinal disorders |
Dry mouth Constipation (see section 4.4) |
Colitis ischaemic Ileus paralytic (see section 4.4) Intestinal perforation (sometimes fatal) Gastrointestinal |
|
necrosis (sometimes fatal) Necrotising colitis (sometimes fatal) Intestinal obstruction | |||
|
Hepatobiliary disorders |
Jaundice cholestatic6 Liver Injury6 Cholestatic liver 6 injury Mixed liver injury | ||
|
Skin and subcutaneous tissue disorders |
Dermatitis allergic Angioedema Contact skin sensitization may occur rarely in those frequently handling preparations of chlorpromazine (see section 4.4) Rash Urticaria Photosensitivity reaction | ||
|
Renal and urinary disorders |
Urinary retention4 | ||
|
Pregnancy, puerperium and perinatal conditions |
Drug withdrawal syndrome neonatal (see section 4.6) | ||
|
Reproductive system and breast disorders |
Priapism | ||
|
General disorders and administration site conditions |
Weight increased |
Temperature regulation disorder Insomnia Agitation | |
|
Investigations |
Antinuclear antibody positive1 |
'may be seen without evidence of clinical disease particularly at the start of treatment
particularly during long term treatment; may occur after the neuroleptic is withdrawn and resolve after reintroduction of treatment or if the dose is increased.
4linked to anticholinergic effects
5in the anterior segment of the eye caused by accumulation of the drug but generally without any impact on sight
6 A premonitory sign may be a sudden onset of fever after one to three weeks of treatment followed by the development of jaundice. Chlorpromazine jaundice has the biochemical and other characteristics of obstructive (cholestatic) jaundice and is associated with obstructions of the canaliculi by bile thrombi; the frequent presence of
an accompanying eosinophilia indicates the allergic nature of this phenomenon. Liver injury, sometimes fatal, has been reported rarely in patients treated with chlorpromazine. Treatment should be withheld on the development of jaundice (see section 4.4).
7 The development of a metallic greyish-mauve coloration of exposed skin, the cornea, the retina and conjunctiva has been noted in some individuals, mainly females, who have received chlorpromazine continuously for long periods (four to eight years).
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme at: www.mhra.gov.uk/yellowcard
4.9 Overdose
Symptoms
Symptoms of chlorpromazine overdosage include drowsiness or loss of consciousness, hypotension, tachycardia, ECG changes, ventricular arrhythmias, hypothermia, Parkinsonism, convulsions and coma. Severe extrapyramidal dyskinesias may occur.
Treatment
Treatment should be symptomatic with continuous respiratory and cardiac monitoring (risk of prolonged QT interval) until the patients conditions resolve.
If the patient is seen sufficiently soon (up to 6 hours) after ingestion of a toxic dose, gastric lavage may be attempted. Pharmacological induction of emesis is unlikely to be of any use. Activated charcoal should be given. There is no specific antidote. Treatment is supportive.
Generalised vasodilation may result in circulatory collapse; raising the patient's legs may suffice. In severe cases, volume expansion by intravenous fluids may be needed; infusion fluids should be warmed before administration in order not to aggravate hypothermia.
Positive inotropic agents such as dopamine may be tried if fluid replacement is insufficient to correct the circulatory collapse. Peripheral vasoconstriction agents are not generally recommended; avoid the use of adrenaline.
Ventricular or supraventricular tachy-arrhythmias usually respond to restoration of normal body temperature and correction of circulatory or metabolic disturbances. If persistent or life threatening, appropriate antiarrhythmic therapy may be considered. Avoid lidocaine and, as far as possible, long acting anti-arrhythmic drugs.
Pronounced central nervous system depression requires airway maintenance or, in extreme circumstances, assisted respiration. Severe dystonic reactions usually respond to procyclidine (5-10mg) or orphenadrine (20-40mg) administered intramuscularly or intravenously. Convulsions should be treated with intravenous diazepam.
Neuroleptic malignant syndrome should be treated with cooling. Dantrolene sodium may be tried.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic Group: Antipsychotics, ATC Code: N05AA01 Chlorpromazine is a phenothiazine neuroleptic.
Although the precise mechanism whereby the therapeutic effects of chlorpromazine are produced is not known, the principal pharmacological actions are neuroleptic, resulting in the favourable modification of psychotic symptoms. Chlorpromazine also exerts sedative and anti-emetic activity. It has alpha-adrenergic blocking and weaker anticholinergic activities. It is an inhibitor of dopamine and it inhibits prolactin-release-inhibitory factor (considered to be dopamine), thus stimulating the release of prolactin. Chlorpromazine has serotonin blocking and weak antihistaminic properties. It inhibits the heat-regulating centre so that the subject tends to acquire the ambient temperature.
5.2 Pharmacokinetic properties
Absorption
Chlorpromazine is rapidly absorbed in the body and it undergoes first-pass metabolism in the gut wall.
Distribution
Chlorpromazine is widely distributed in the body and crosses the blood-brain barrier. The drug is highly bound to plasma protein. It readily diffuses across the placenta. Small quantities have been detected in milk from treated women.
Biotransformation
It is metabolised in the liver and paths of metabolism include hydroxylation and conjugation with glucuronic acid, N-oxidation, oxidation of a sulphur atom and dealkylation.
Elimination
It is excreted in the urine and bile.
Whilst plasma concentration of chlorpromazine itself rapidly declines excretion of chlorpromazine metabolites is very slow.
Paediatric population
Children require smaller dosages per kg than adults.
5.3
Preclinical safety data
There are no preclinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Lactose B.P.
Maize Starch B.P.
Povidone B.P.
Sodium Starch Glycollate B P. Magnesium Stearate B.P. Opadry Y-1-7000
6.2 Incompatibilities
None.
6.3 Shelf Life
4 years (48 months).
6.4 Special Precautions for Storage
Store in a cool dry place.
Protect from light and heat.
Keep out of reach of children.
6.5 Nature and contents of container
Polypropylene securitainers with tamper evident polypropylene caps. Pack sizes: 28,50,100,250,500,1000 and 5000 tablets.
Not all pack sizes may be marketed.
6.6 Special precautions for disposal
Not applicable.
7 MARKETING AUTHORISATION HOLDER
Mercury Pharmaceuticals Ltd No. 1 Croydon,
12-16 Addiscombe Road, Croydon CR0 0XT, UK
8. Marketing Authorisation Number
PL 12762/0110
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
02/12/2008
10 DATE OF REVISION OF THE TEXT
14/10/2015